NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

TReatment Approaches and bIomarkers preValence in bladdEr Cancer in RuSsian Federation

RecruitingN/A

Sponsor: AstraZeneca

Conditions: Bladder Cancer

Countries: Russia

A multicentre observational study on treatment approaches and HER2 positive status prevalence in different stages of bladder cancer and PD-L1-positive status in metastatic bladder cancer in Russian Federation

Eligibility overview

Sex: ALL

Age: 18 Years to —

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion Criteria:

* Age ≥ 18 years;
* Signed ICF, including consent for FFPE tumor tissue sample testing;
* Confirmed diagnosis of urothelial bladder cancer at NMIBC, MIBC, or mBC stage at study entry;
* For patients with NMIBC: 1. TURBT performed at least 1 month but not more than 12 months prior to study entry; 2. Presence of ≥1 high-risk feature:

  * T1 tumor
  * High grade/G3 tumor
  * CIS (carcinoma in situ)
  * Multiple and recurrent and large (with diameter of largest tumor ≥3 cm) tumors (all conditions must be met in this point);
* For patients with MIBC: Сystectomy performed at least 2 months but not more than 12 months prior to study entry;
* For patients with mBC: mBC diagnosed during 12 months prior to study entry;
* Availability of medical history data;
* Availability of FFPE tumour tissue sample obtained during biopsy and/or surgery.

Exclusion Criteria:

• Participation in any interventional trial since the urothelial bladder cancer diagnosis.

Locations (20)

Arkhangelsk, Russia
Barnaul, Russia
Chelyabinsk, Russia
Krasnodar, Russia
Krasnoyarsk, Russia
Makhachkala, Russia
Moscow, Russia
Moscow, Russia
Moscow, Russia
Nizhny Novgorod, Russia
Novosibirsk, Russia
Obninsk, Russia
Omsk, Russia
Saint Petersburg, Russia
Saint Petersburg, Russia
Saint Petersburg, Russia
Tomsk, Russia
Tyumen, Russia
Ufa, Russia
Yekaterinburg, Russia